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Abstract 
Rationale 
Insulin Like Peptide 5 (INSL5) is a hormone produced by enteroendocrine L-cells in the colon that has 
recently been implicated in the control of metabolic homeostasis. However, research into its 
physiology has been hindered by the reported unreliability of commercially available immunoassays 
and additional detection assays would benefit this emerging field. 
Methods 
Peptides from purified murine L-cells and homogenates from both human and mouse colonic tissues 
were extracted by precipitating larger proteins with acetonitrile. Untargeted LC/MS/MS analyses 
followed by database searching, was used to detect and identify various INSL5 gene derived peptides 
and characterize their precise sequence. A similar approach was developed to quantify INSL5 levels 
in primary intestinal culture supernatants after purification and concentration by solid phase 
extraction. 
Results 
Mass spectral analysis of purified enteroendocrine cells and tissue homogenates identified the exact 
sequence of A- and B-chains of INSL5 endogenously expressed in L-cells. Differences in the 
endogenously processed peptide and the Swissprot database entry were observed for murine INSL5, 
whereas the human sequence matched previous predictions from heterologous expression 
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experiments.  INSL5 was detected in the supernatant of human and mouse primary colonic cultures 
and concentrations increased after treatment with a known L-cell stimulus. 
Conclusions 
The first LC/MS/MS based method capable of the detection and semi-quantitative analysis of 
endogenous INSL5 using MS based techniques has been demonstrated. The methodology will enable 
the identification of stimulants for INSL5 secretion from murine and human primary colonic 
epithelial cultures. 
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Introduction  
Insulin-like peptide 5 (INSL5) is a member of the insulin/relaxin gene family sharing a common 
structural signature comprised of an A- and B-chain with a conserved cysteine bridging pattern 
(Figure 1) [1]. INSL5 is expressed at highest levels in the colon of both mice and humans, with lower 
expression found for example in thymus and testis [1,2] and within the colon it is expressed in 
enteroendocrine L-cells [3], which also secrete glucagon-like peptide-1 (GLP-1) [4] and peptideYY (PYY) 
[4]. Liu and collaborators showed that INSL5 stimulates the G-protein coupled receptor RXFP4 
(GPR100 or GPCR142) but no precise physiological function of the peptide was initially identified [5]. 
Since then INSL5 has been implicated in the regulation of metabolism, either by affecting glucose 
tolerance through an impact on insulin production [6], insulin secretion [7] or the regulation of hepatic 
glucose production [8] or through the stimulation of food-intake [3]. Consistent with an orexigenic 
function, Grosse et al. reported a fall in INSL5 plasma levels after refeeding of starved mice, 
however, observed poor reproducibility and batch dependence of several commercially available 
immunoassays. The detected plasma concentrations varied widely [3], but generally were in the 
range of 1-100 pg/ml, whereas a recent report detected ~100-fold higher INSL5 levels in human 
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serum [9]. Importantly, however, with commercial immunoassays we were unable to detect INSL5 
either in supernatants or lysates of primary colonic epithelial cultures that we routinely use to 
investigate secretion of GLP-1 and PYY from L-cells. As we were able to detect INSL5 in these 
cultures by immunohistochemistry [3], we aimed to develop an independent assay suitable for the 
investigation of stimulus secretion coupling in these in vitro systems.   
 
 
Figure 1. Sequences and disulphide bond positions of murine and human mature INSL5 peptides 
compared to human insulin. A: Murine INSL5 protein as designated by Swissprot, # denotes the 
additional arginine residue compared to the Phoenix peptide. B: The structure of the Phoenix murine 
INSL5 peptide, * denotes the additional serine residue compared to the Swissprot sequence in A. C: 
The structure of human INSL5 as designated by Swissprot and D: Structure of human insulin for 
comparison. 
 
Over the last two decades, mass spectrometry (in combination with electrospray ionisation) has 
become a powerful tool in the analysis of peptides, both for quantitative analysis and for 
identification of potential new functional peptides. Studies have included the analysis of primary 
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islet cell cultures where significant numbers of glucagon gene products were identified [10]. More 
targeted mass spectrometry techniques using triple quadrupole systems have been employed to 
monitor peptides such as GLP-1 7-36 and 9-36 in established colorectal cell lines [11]. Furthermore, 
mass spectrometric approaches have proven to be sensitive enough to detect some gut hormone 
peptides at physiological (usually low pM or pg/ml) levels in circulating plasma [12,13].  Mass 
spectrometry has also been successfully applied to the detection and quantitation of peptides from 
the insulin/relaxin family. In contrast to most immunoassays, mass spectrometry can readily 
distinguish between peptides with only subtle differences as for example endogenous human insulin 
and the closely related Humalog, which is isobaric and differs only by a transposition of the proline 
and lysine residues at the C-terminal end of the A chain [14]. This study also demonstrated that mass 
spectrometric approaches can reach lower limits of quantitation in the region of 50 pg/mL in plasma 
for most of the insulin analogues. We thus investigated the possibility of using a mass spectrometry 
based assay for INSL5 that would also allow the characterisation of the exact peptide sequence of 
stored and secreted products derived from the prepropeptide.  
 
Materials and methods: 
Materials: 
All reagents were purchased from Sigma Aldrich (Poole, UK), except acetonitrile, methanol and 
trypsin that were purchased from Fisher Scientific (Loughborough, UK), Matrigel and Draq5 that 
were purchased from BD Bioscience (Oxford, UK) and Y27632 from Tocris Bioscience (Bristol, UK). 
Murine INSL5 peptide was purchased from Phoenix Pharmaceuticals (Burlingame, CA, USA).  
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Peptide extraction from FACS sorted murine L-cells  
Single cell suspensions of colonic epithelial cells were prepared with slight modifications to a 
previously described  procedure [15]. All animal procedures were approved by the University of 
Cambridge Animal Welfare and Ethical Review Body and conformed to the Animals (Scientific 
Procedures) Act 1986 Amendment Regulations (SI 2012/3039). The work was performed under the 
UK Home Office Project License 70/7824. Briefly, colons from 3-6 months old mice expressing the 
reporter fluorophore Venus under the control of the glucagon promoter [16] were harvested and 
washed with PBS. The external muscle layer was removed and tissue was incubated in PBS with 
15mM EDTA and 0.5mM DTT for 10 minutes, transferred into cold PBS with Y27632 (10M) and 
shaken for 30s to detach crypts. This was repeated 5 times and crypts and cell clumps detached from 
the tissue were centrifuged (300 x g, 5min) after each step. Pooled sediments were digested into 
single cells in 0.25% Trypsin EDTA for 5-10min at 37C. Single cells were washed and kept in cold HBSS 
with 0.1% BSA, Y27632 (10M), DAPI (1g/mL) and Draq5 (5M). Single live L-cells were isolated 
based on forward and side scatter and Venus, DAPI and Draq5 fluorescence within 4 hours using a 
FACSJazz (BD Biosciences, Singapore) at the Cambridge NIHR BRC Cell Phenotyping Hub. Peptides 
were extracted using a method adapted from a validated approach for enriching peptides from 
plasma [17–19], where a total of 6000-8000 positive cells were sorted and lysed directly into 800 µL of 
80% ACN in water (v/v) in a Protein Lobind Eppendorf tube. Samples were centrifuged for 5 minutes 
at 10,000 x g to pellet the proteins and the supernatant was transferred to a fresh tube and 
evaporated to dryness in an Eppendorf 5301 vacuum concentrator. Reduction and alkylation of 
disulphide bonds was performed (as described below) prior to LC/MS analysis, and 10 µL was 
injected onto the system. 
Reduction and alkylation 
The sorted cell peptide residue was reconstituted into 25 µL of 50 mM ammonium bicarbonate 
containing 10 mM dithiothreitol and heated at 60 ºC for 60 minutes. 5 µL of 100 mM iodoacetamide 
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in 50 mM ammonium bicarbonate were mixed in, and the samples were stored in the dark for 30 
minutes at room temperature and subsequently exposed to light for at least 30 minutes. 5 µL of 1% 
formic acid in water (v/v) was added prior to injection on the LC/MS system.  
 
 
Tissue homogenisation: 
Mice 3–6 months old were sacrificed by cervical dislocation and the colon was excised. For human 
colon fresh surgical specimens were obtained from Tissue Bank at Addenbrooke’s Hospital, 
Cambridge, UK, stored at 4°C and processed within a few hours of surgery. Work on human tissues 
was approved by the Research Ethics Committee under license number 09/H0308/24. 
 Tissue was washed with PBS and the outer muscle layer removed. 20-100mg of tissue was then 
minced and transferred into a fast prep lysing matrix D tube (MP Biologicals, Santa Ana, USA). 
Peptides were extracted from the tissue by adding 800 µL of 80% ACN in water (v/v) to the tissue 
pieces, and performing homogenisation using a Fast-Prep 24 instrument (MP Biologicals) with four 
cycles of 40s homogenization (6m s-1). Precipitated proteins and tissue debris were pelleted by 
centrifugation (5 minutes at 10,000 x g) and the supernatant transferred to Lobind tubes for 
evaporation at room temperature. All extraction steps were performed on ice or at 4⁰C to minimize 
peptide loss through enzymatic degradation and Lobind tubes were used throughout to counter 
adsorptive losses to plastic consumables. Dried extracts were reconstituted into 200 µL of 0.1% 
formic acid in water (v/v) and loaded onto a Waters HLB µElution SPE plate, primed with 200 µL of 
methanol and 200 µL of reagent grade water before loading of the sample. Samples were washed 
with 200 µL of 0.1% formic acid in water (v/v) and 200 µL of 5% methanol & 1% acetic acid in water 
(v/v) before elution with 2 x 25 µL of 60% methanol in water with 10% acetic acid (v/v). For intact 
peptide studies, the extract was immediately diluted with 50 µL of 0.1% formic acid in water (v/v) 
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prior to injection onto the LC/MS system. To confirm the sequence of the A and B chains, the SPE 
eluent (50 µL) was dried under oxygen free nitrogen (heated to 40 ºC) on a SPE Dry evaporator 
system (Biotage, Upsalla, Sweden) prior to reduction and alkylation.  
 
 
Nano LC/MS analysis of sorted cells and tissue homogenates 
Peptide extracts were analysed using a Thermo Fisher Ultimate 3000 nano LC system coupled to a Q 
Exactive Plus Orbitrap mass spectrometer (ThermoScientific, San Jose, USA). The analysis was 
performed using nano flow based separation and electrospray approaches due to the low amount of 
material present in the samples. The extracts were injected onto a 0.3 x 5 mm peptide trap column 
(ThermoFisher Scientific) at a flow rate of 20 µL/minute and washed for 10 minutes before switching 
in line with a 0.075 x 250 mm nano easy column (ThermoFisher Scientific) flowing at 300 nL/min. 
Both nano and trap column temperatures were set at 45 ºC during the analysis. The buffers used for 
nano LC separations were A: 0.1% formic acid in water (v/v) and B: 0.1% formic acid (v/v) in 80:20 
ACN:water. Initial starting conditions were 2.5% B (equating to 2% ACN), and held for 5 minutes. A 
ramp to 50 % B was performed over 145 minutes, and the column then washed with 90% B for 20 
minutes before returning to starting conditions for 20 minutes, totalling an entire run time of 190 
minutes. Electrospray analysis was performed using a spray voltage of 1.8 kV, the tune settings for 
the MS used an S-lens setting of 70 v to target peptides of higher m/z values. A full scan range of 400 
– 1600 m/z was performed at a resolution of 75,000 before the top 10 ions of each spectrum were 
selected for MS/MS analysis. Existing ions selected for fragmentation were added to an exclusion list 
for 30 seconds.  
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Endogenous peptide identification. 
The acquired LC/MS files were searched using Peaks 8.0 software (Waterloo, ON, Canada) against 
the mouse and human Swissprot databases (Downloaded on 06-May-2016). A no-digest setting was 
used, which enabled peptides of up to 65 amino acids in length being matched, and precursor and 
product ion tolerances were set at 10 ppm and 0.05 Da respectively. A fixed post translational 
modification of carbamidomethylation was applied to cysteine residues, whilst variable 
modifications included methionine oxidation, N-terminal pyro-glutamate, N-terminal acetylation and 
C-terminal amidation.  A false discovery rate value of 1% was used to filter the results, with a 
minimum of 1 unique peptide also required. 
 
Secretion of INSL5 from primary murine and human colon cultures 
Following the identification of the reduced and alkylated A and B chains from INSL5 in the nano 
LC/MS/MS analysis, an assessment of the intact and secreted form of INSL5 was performed. Primary 
mixed epithelial cultures of human and mouse colon were generated using established methods 
[4,16]. Briefly, human and mouse tissues were washed and minced and digested with collagenase XI 
(respectively 0.5mg/mL and 0.4mg/mL) twice for 10min and twice for 15minutes. Crypts/cell clumps 
were collected and washed twice in culture medium (high-glucose DMEM supplemented with 10% 
Fetal Bovine Serum (FBS), 100 U/mL penicillin and 0.1 mg/mL streptomycin (P/S), and 2 mM L-
glutamine) before being plated on Matrigel coated plates. 16-36h after plating culture medium was 
replaced by washing with HEPES-buffered saline ((mM): NaCl (138), KCl (4.5), HEPES (10), CaCl2 (2.6), 
MgCl2 (1.2), NaHCO3 (4.2), NaH2PO4 (1.2), pH adjusted to 7.4 with NaOH) with 0.001% BSA, diprotin A 
(30mM) and phosphoramidon (10µM). Subsequently wells were incubated for 1h at 37ºC in this 
buffer (control) or in the additional presence of forskolin (10µM), 3-Isobutyl-1-methylxanthine 
(IBMX, µM) and glucose (10mM). Supernatants were collected and cleared of cells and debris by 
centrifugation (5min, 2000g) and stored at -70ºC until extraction. Samples were extracted using the 
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SPE method described above, and were analysed without reduction and alkylation to assess the 
intact form of INSL5.  
 
High flow rate analysis of primary colonic culture supernatants 
A full scan analysis was performed on the extract using a high flow rate based LC/MS approach using 
a 300 µL per minute flow rate on the same instrumentation as described above. Solvents used for 
the separation were A: 0.1% formic acid in water (v/v) and B: 0.1% formic acid in ACN (v/v). 10 µL of 
extract was injected onto a Waters (Elstree, UK) HSS T3 2.1 x 50 mm UPLC™ column at a starting 
condition of 7.5 % B, and eluted using a linear gradient up to 40 % B over 16 minutes. The column 
was washed for 2 minutes at 90% B and returned to starting conditions for 2 minutes, totalling a run 
time of 20 minutes. A total of 40 µL of sample was injected onto the column for analysis. Mass 
spectrometry was performed using positive electrospray mode with a needle voltage of 3 kV, gas 
settings of 55 and 10 for sheath gas and aux gas flow rates. The temperature of the gas was set at 
350 ⁰C and the transfer capillary at 350 ⁰C and a s-lens value of 70V. Full scan data was acquired over 
an m/z range of 500-1600, using a resolution of 70,000 and a maximum fill time of 200 ms. Tandem 
mass spectra were collected on the top 3 ions of each spectrum with a minimum m/z of 100, and a 
resolution of 17,500. Database searching was performed as mentioned earlier. The Phoenix 
Pharmaceutical INSL5 protein was characterised using this high flow rate analysis, where 10 µL of a 1 
µg/mL standard was injected onto the LC/MS system. 
 
Precision and accuracy of the SPE extraction approach 
An attempt was made to develop a quantitative methodology for the intact murine INSL5 peptide 
using a commercially sourced murine INSL5 peptide. However, the characterisation of the peptide 
demonstrated it was different from the endogenous peptide, and therefore could not be used to 
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generate a fully quantitative methodology. The peptide was however used to assess the sensitivity, 
precision and accuracy of the SPE extraction approach for a very closely related peptide to the 
endogenous protein. A calibration line of Phoenix INSL5 protein was generated in 0.001% BSA in 
0.1% formic acid (v/v) over a range of 0.1 to 10 ng/mL. Seven calibration standards were generated 
(0.1, 0.25, 0.5, 1.0, 2.5, 5.0 and 10 ng/mL), 0.5 mL of each standard were extracted via the SPE 
method described above, and 40 µL of sample was injected onto the LC/MS system. Four levels of 
QC were generated (0.1, 0.3, 1 and 8 ng/mL) and extracted six times in order to assess the precision 
and accuracy of the analysis. The calibration line followed a quadratic fit, as no internal standard was 
available to be able to correct for ionisation or adsorptive losses during the extraction process. 
Recovery of the peptide from the BSA solution was assessed by analysing a spiked solution before 
and after extraction at a concentration of 8 ng/mL.  
 
Results and discussions. 
Nanoflow LC/MS analysis of purified cells and homogenised tissue. 
Initial analysis was performed on sorted colonic murine L-cells as these are the main source of INSL5 
in the body[3,20]. INSL5 derived peptides were successfully detected after reduction/alkylation (Figure 
2a). Interestingly, the extraction method was also sufficiently sensitive to detect INSL5 derived 
peptides in crude tissue homogenates from both murine (not shown) and human colon (Figure 2b). 
The database search matched peptides throughout the entire INSL5 prohormone sequence except 
from the signal peptide (amino acid residues 1-21), and three dibasic cleavage sites. These included 
the full-length A and B chain peptides (and fragments of) and a significant number of peptides from 
the connecting-peptide region. Interestingly, the Swissprot entry for the connecting peptide suggests 
that it is one single peptide (residues 49-114 for both the mouse and human peptides), however the 
data we have generated suggest that the connecting peptide is cleaved into two distinct peptides 
(and associated break down products) in both the murine and human tissues. We considered the 
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true A and B chains to be the matched peptides that were present at the highest levels (based on 
peptide peak area), and shorter peptides were considered degradation products. 
 
Figure 2. Peptides from the INSL5 prohormone detected in murine and human colonic samples.  
Each box represents a sequence detected and identified by LC-MS/MS that matches the mouse (top) 
or the human (bottom) INSL5 sequence and is represented above the corresponding sequence. Grey 
levels indicate the peptide peak area (log10 scale) from a representative experiment of mouse 
sorted colonic L-cells and homogenates of human colonic tissue. Some post translational 
modifications to specific amino acids were detected and are indicated by a white box at the position 
of the modification: the methionine in the A chain was present in both a reduced and oxidised (O) 
form, and the N-terminal of the Human A chain only displayed the pyro-glutamate form (P), as is well 
documented. The sequence specified in the Swissprot database in indicated by the black bars below 
the sequence. 
The sequences of the A and B peptides with the highest peak area essentially matched the peptides 
specified at the Swissprot database. However, while the human A-chain was confirmed to possess an 
N-terminal pyroglutamate [21], we did not observe the N-terminal arginine specified for the mouse A-
  
This article is protected by copyright. All rights reserved. 
chain on Swissprot in whole tissue extracts. Instead the predominant A-chain peptide started with 
the subsequent aspartate and only in extracts from FACS purified L-cells could we detect an A-chain 
with the N-terminal arginine at an ~200-fold reduced abundance compared to the predominant 
form. A likely explanation for these findings is that the N-terminal arginine containing A-chain 
represents a processing intermediate and that this amino acid is removed in the mature murine 
INSL5. We also detected murine A-chain peptides with an oxidized methionine in lysed FACS sorted 
cells (Figure 2a).  The oxidised form of the A-chain eluted well before the non-oxidized form, 
therefore excluding an oxidation artefact during ionization, but we cannot exclude the possibility 
that the oxidation occurs at other time points during sample processing rather than representing a 
true secreted hormone variant. 
We also analysed a synthetic murine INSL5 purchased from Phoenix by MS/MS and confirmed the 
sequences given in the accompanying data sheet.  The A-chain starts with the aspartate, similar to 
the predominant form we found endogenously produced in L-cells. The B-chain of the Phoenix 
peptide, however, incorporated an N-terminal serine, which is thought to be part of the signal 
peptide as stated on Swissprot and accordingly appeared not to be present in the mature INSL5 
peptide isolated or secreted from L-cells.  
The combination of the multiple tissue sources in the LC/MS data and database searching results 
allowed us to propose a mature mouse INSL5 sequence (shown in Figure 3D) differing subtly from 
the predicted form indicated in the Swissprot database (Figure 1 A) and the synthesised form 
commercially available from Phoenix (Figure 1B). Our data corroborates the sequence of 
endogenous human INSL5 that is present in the Swissprot database (Figure 1C). Mass spectrometric 
techniques have been applied to human INSL5 protein before to characterise the prohormone 
cleavage sites after heterologous expression in a mammalian cell line (Cos7 co-overexpressing furin),  
identifying an identical mature form to the one reported here [5]. Whilst MS has been used to verify 
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the sequence of recombinant and synthetically synthesised INSL5  variants [22], to our knowledge, no 
endogenously expressed INSL5 has previously been analysed using LC/MS.  
LC/MS analysis of Intact endogenous and synthetic INSL5 peptides. 
As INSL5 is supposed to be secreted from the colon, we assessed if we could detect the peptide in 
the supernatant of human and murine colonic primary cultures. Initially we detected murine INSL5 in 
culture supernatants after reduction/alkylation, the A and B-chain species resembling the ones 
observed in whole tissue lysates. Both human and mouse INSL5 could, however, also be detected 
intact, as can be seen in the insets of Figures 3 A and C. The inset of Figure 3A shows the [M+5H]5+ 
charge state of the endogenous murine INSL5, which suggests that the peptide had a molecular 
weight that was calculated as 5025.412 Da, which is very close to the theoretical monoisotopic mass 
of the peptide with the sequence described in this study (5025.392, obtained from the chemical 
formula for murine INSL5 C213H349N61O65S7), and has an error of 3.97 ppm. The inset of Figure 3C 
shows the [M+5H]5+ charge state of the human INSL5, which suggests that the peptide had a 
molecular weight that was calculated as 5041.43 Da, which is very close to the theoretical 
monoisotopic mass of the peptide (5041.29, obtained from the chemical formula for human INSL5 
C213H341N57O70S7), and has an error of 27 ppm. The fragmentation pattern of the [M+5H]5+ charge 
states of both analytes was performed and both had several common fragmentation products, 
which were also seen with the synthetic Phoenix peptide standard (Figures 3A-C). The synthetic 
murine INSL5 reference standard was obtained from Phoenix pharmaceuticals to develop a 
quantitative LC/MS methodology, so that the levels of INSL5 could be measured in secretion 
samples. The initial LC/MS analysis of the intact Phoenix murine INSL5 peptide agreed with the 
certificate of analysis, and the data showed the standard contained a protein of 5112.47 Da, which, 
when compared to the theoretical molecular weight of this isoform of INSL5 of 5112.42, gave an 
accuracy of 9.7 ppm. The MS/MS fragmentation pattern of the peptides [M+6H]6+ charge state was 
recorded and is displayed in Figure 3B. All fragmentation data was manually matched against 
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theoretical fragments as the Peaks software was unable to match fragments of peptides that contain 
disulphide bonds.  
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 INSET A
INSET B
INSET C 
Figure 3. Product ion spectra of three INSL5 (A= mouse (from stimulated secretion sample), B= 
synthetic mouse (Phoenix), C= human (from stimulated secretion sample)), showing significant 
similarities in fragmentation patterns. The tandem mass spectrum of the Phoenix INSL5 [M+6H]6+ 
charge state was used as it generated a better fragmentation spectrum than the [M+5H]5+ charge 
state. Ions that are labelled in panel A indicate positive identifications of the fragmentation product 
represented in D. The inset shows the [M+5H]5+ charge state for each peptide isoform, with which 
the intact peptides molecular weight was calculated.  D: Proposed structure of mouse INSL5 and its 
fragmentation pattern. 
 
Singly charged product ions were detected that corresponded to C terminal fragments of the B chain 
peptides up to the position of the disulphide bonded cysteines, whilst highly charged and large (y ion 
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type) product ions were generated from fragmentation events at the N-terminal region of the A 
chain. Fragments of the C-terminal portion of the B chain were the most abundant, including the m/z 
448.23, 535.26 and 606.29 ions which correspond to the y3, y4 and y5 fragments (Figure 3). The m/z 
828.31 ion is believed to be coming from a species that includes the C terminal cysteine residue of 
the A chain linked to the cysteine residue of the B chain and including the five other C-terminal 
amino acids, therefore comprising a disulphide bonded fragment The expected m/z of this 
hypothetical A and B chain linked fragment is 828.31, which is identical to the experimentally 
acquired value (to 2 dp). An additional ion of m/z 941.40 was characterised as having this linked 
disulphide bond with either an additional leucine or isoleucine attached (Figure 3D). However, as 
these two amino acids are isobaric, the exact composition of the product ion cannot be confirmed. 
Other fragment ions that are present in the MS/MS spectrum appear to be derived from large and 
highly charged ([M+4H]4+ and [M+5H]5+ species) peptide fragments. These are likely fragmentation 
products of the peptide where N-terminal residues are lost from the A chain peptide. Five specific 
m/z ions of interest are 1229.32, 1200.31, 1168.30, 1150.54 and 1122.28, which correspond to 
peptides which have masses of 4913.28, 4797.24, 4669.2, 4598.16 and 4485.16 respectively. 
Comparing these masses to the calculated intact molecular weight of the mouse INSL5 peptide 
(5025.44Da) suggests that the peptide loses sequential masses of 112.13, 116.04, 128.04, 71.04 and 
113.04 Da. The last three masses correspond well to the sequential loss of Q, A and L from the INSL5 
A-chain N-terminus (DLQAL), however, the initial loss of the N-terminal amino acids would be 
expected to give sequential mass differences of 115.09 Da (D) and 113.16 Da (L). This perhaps 
indicates that the N-terminal of the A chain undergoes an alternative fragmentation procedure to 
the normal peptide backbone fragmentation pathway.  
 
The mass spectrometric analysis of the Phoenix peptide suggests that the molecule was as sold, 
however, as mentioned previously the peptide has an N-terminal serine residue on the B chain, 
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which differs from both the Swissprot specified sequence and the detected endogenous peptide. 
The Phoenix peptide standard did in fact contain a small amount of the endogenous peptide, 
however this appeared to be present as an impurity, as its peak area was approximately 1.5% of that 
attributed to the Phoenix INSL5 with the additional N-terminal serine residue. The difference in 
amino acid sequence between these two versions of murine INSL5 might not affect immunoassay 
based quantitation methods if the antibodies epitope is elsewhere in the INSL5 three-dimensional 
structure. However, the addition of the serine residue means that mass spectrometric analysis 
approaches are compromised due to the significant change in the peptides mass. One potential 
approach to use the Phoenix peptide for quantitative studies is to reduce and alkylate the peptide, 
separating the two chains and analysing the A-chain only, as this is identical to the endogenous 
version. However, using this approach would result in the loss of structural information, where any 
cleavages or modifications to the B chain would be lost if only the A chain is monitored. 
 
Assessment of the precision and accuracy of the SPE extraction. 
The precision and accuracy of the SPE based LC/MS method was assessed over a concentration 
range of 0.1 to 10 ng/mL using the Phoenix peptide. Acceptance criteria for the analysis were 20% 
CV and RE for non LLOQ concentrations and 25% CV and RE at the LLOQ. These acceptance criteria 
are used for biological method validation, which we believe were appropriate for this method. The 
seven-point calibration line demonstrated a quadratic fit, and resulted in a R2 value of 0.9966, where 
one of the 14 standards needed to be deactivated as it was outside the 20% acceptance criteria 
(Figure 4). The overall precision and accuracy values of the QC’s can be seen in Figure 4, therefore 
demonstrating the method can generate good results across the selected calibration range.  
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Figure 4. Calibration line of extracted Phoenix mouse INSL5 protein over the calibration range of 0.1 
to 10 ng/mL, demonstrating a quadratic fit. QC statistics of the precision and accuracy test are 
included as an inset (n=6 at each level), showing good quantitative performance of the extraction 
method. 
 
The recovery of the extraction method was calculated as 59%, however demonstrated good 
reproducibility as the %CV of the 5 recovery assessments was less than 5.3%. This indicated that 
although the recovery was low, the reproducibility of the recovery was high, and suggested that 
further optimisation could potentially increase the sensitivity of the method through increasing the 
elution efficiency of the peptide from the SPE cartridges. 
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Quantification of INSL5 secretion in human and mouse colonic primary cultures 
The primary colonic tissue cultures were incubated for one hour with or without Forskolin (10M), 
IBMX (10M) and Glucose (10mM), a cocktail well known to dramatically stimulate secretion of 
glucagon-like peptide-1 and peptideYY from L-cells [4,16], and the supernatant extracted using the SPE 
methodology. The murine and human incubations were pooled and then extracted in triplicate to 
assess the effect of these stimuli on the release of INSL5 from the tissues.  
The LC/MS analysis of the murine samples showed that the level of basal secretion was very close to 
the detection limit of the instrument, however the peptide generated a peak that gave a signal to 
noise value of between 4 and 5. The stimulatory condition (Forskolin/IBMX/glucose) increased the 
amount of INSL5 detected in the supernatant approximately 25-fold in one hour incubations (Figure 
5). The reproducibility of the SPE extraction on the culture supernatants was assessed by calculating 
the %CV of the endogenous INSL5 peptide peak area in the four measurements. These returned %CV 
values of 13% and 11% for the basal and stimulated samples respectively, which are acceptable but 
could be improved further with internal standardisation approaches. 
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Figure 5. Example chromatograms of intact mouse INSL5 under basal conditions (5A) and stimulated 
conditions (5B) showing peak areas and relative noise levels. RT: Retention Time; MA: Measured 
Area. The peptide peak areas (from four extractions of a pooled sample) demonstrates good 
reproducibility, and clear difference between the basal and stimulated states (5C). Error bars 
indicate one standard deviation. The %CV of the four measurements was 13% and 11% for the basal 
and stimulated samples respectively. 
 
The analysis of the human primary culture supernatant failed to detect the peptide in any of the 
samples analysed using a high flow analysis. Therefore, the extract was re-analysed using the 
described nano LC/MS approach, enabling the identification of INSL5 in the stimulated sample with a 
signal to noise value of ~20, generating a suitable MS/MS spectrum (Figure 3C). However, the signal 
from the basal sample was still too low to detect the peptide in its intact (disulphide bonded) form. 
Further experiments using tissue from a more distal region of the colon combined with 
reduction/alkylation of the extracts allowed us to detect INSL5 both in basal and stimulated 
conditions (data not shown). This suggests that further work is needed to improve the sensitivity of 
the methodology before it can be reliably applied to study INSL5 secretion from human derived 
cultures, but might also reflect that INSL5 content increases towards the more distal colon, whereas 
the exact source of human colonic tissue from surgery is somewhat varied. The possibility of 
protease derived losses of INSL5 from the human and murine secretion experiment is also a 
potential cause of sensitivity issues. Future method development will investigate the addition of 
protease inhibitors to the tissue culture supernatants (as long as they are compatible with cell 
function). However, we believe protease inhibitors were not needed in the ACN solvent in the sorted 
cell and homogenisation analysis, as proteases would be denatured in the 80% ACN solution, and 
not able to cleave peptides after extraction.   
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Further improvements to the human methodology might also involve using the Phoenix murine 
peptide as a surrogate internal standard for the human peptide, to account for potential losses 
during extraction. However, the Phoenix mouse INSL5 peptide is not an ideal surrogate internal 
standard for the endogenous murine peptide because of the low-level impurity of the endogenous 
murine INSL5. Nevertheless, the data has shown that an LC/MS based methodology can be used to 
detect and measure endogenously produced murine INSL5 under different culture conditions, and 
allows comparative studies of the amount of INSL5 secreted. Due to the differences between the 
Phoenix INSL5 and the endogenous mouse peptide, absolute quantitation of the peptide was not 
possible. However, having in mind an unknown degree of error due to the miss-match between the 
Phoenix and the endogenous peptide sequence, quantification of the endogenous peptide peak 
relative to the Phoenix peak gave a rough estimate of 0.5 to 6.3 ng/mL for un- and stimulated 
conditions, respectively.  
 
Conclusions 
This study describes the adaptation of a well characterised extraction method for enriching peptides 
from complex matrices to the lysis of sorted enteroendocrine cells and whole tissue extracts to 
analyse INSL5 content. The initial sorted cell analysis enabled the detection and identification of the 
reduced and alkylated peptides from the gut hormone peptide INSL5. The analysis demonstrated 
good sensitivity, as fewer than 8000 cells were lysed in the analyses. The crude homogenisation 
approach also resulted in the detection of INSL5, albeit in the context of an increased background of 
other peptide fragments, derived from housekeeping proteins, such as histones and actin (data not 
shown), as might be expected from a tissue lysate in which the peptide of interest is only expressed 
in 1/1000 to 1/100 of the cells. The endogenous mouse peptide differed slightly from the Swissprot 
database reference sequence and we suggest this to be changed, as to the best of our knowledge 
this is the first report of a detailed sequence analysis of mature INSL5 from an endogenously 
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expressing and processing source. The endogenously expressed and processed human peptide 
sequence by contrast is identical to the previous prediction from heterologous expression 
experiments [21]. Furthermore, peptidomics analysis of the sorted cell extract and tissue 
homogenates showed that the connecting peptide was actually present as two distinct peptides due 
to the presence of a dibasic cleavage site within the amino acid sequence. This was apparent for 
both the murine and human connecting sequence, and differs from what is stated in the Swissprot 
database. 
The focus of the method development then shifted from identification to quantitation on secreted 
intact INSL5. An SPE based methodology was developed that was capable of extracting INSL5 from 
the supernatant and concentrating it significantly, such that the intact peptide could be detected 
and quantified using a high flow rate analysis approach. Whilst a high flow rate analysis is less 
sensitive than nano LC/MS analyses, it is more robust and has significantly higher throughput. High 
flow analysis has been used previously to show how effective LC/MS/MS is as a quantitative tool for 
peptides and proteins, even generating comparable data against clinical analyser systems [23].  
Unfortunately, the Phoenix murine INSL5 that was purchased for generating a quantitative assay 
also demonstrated a different sequence from the endogenous peptide, therefore future LC/MS 
quantitative strategies need to be focussed first on obtaining a modified reference standard. 
Further, and significant, methodology developments will be required for detecting and quantifying 
INSL5 in plasma, as we expect these to be in the pM (pg/ml) range, similar the intestinal hormones 
GLP-1 and PYY, which are co-secreted from L-cells. It is likely that in order to detect endogenous 
INSL5 in plasma, large plasma sample volumes could be required (not feasible in rodent models), 
however, nano LC/MS/MS and targeted SRM detection could achieve the required sensitivity with 
limited volume samples. Furthermore, the investigation of a hybrid immuno-affinity LC/MS/MS 
analysis approach might be required, which was successfully employed to quantify circulating 
proglucagon products in human plasma [13].  
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However, here we demonstrated an approach to measure secreted and cellular INSL5 levels in 
mouse and human samples that should enable further research investigating the production and 
secretion of this peptide recently implicated to play a role in metabolic homeostasis.  
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